Evidence map›Paper›PMID 34820666›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2021

Analysis of 2-methylcitric acid, methylmalonic acid, and total homocysteine in dried blood spots by LC-MS/MS for application in the newborn screening laboratory: A dual derivatization approach.

Joshua A Dubland, Bojana Rakić, Hilary Vallance, Graham Sinclair

Open access · goldAbstract read
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Joshua A DublandDepartment of Pathology and Laboratory Medicine, British Columbia Children's Hospital, Vancouver, BC, Canada.
Bojana RakićDepartment of Pathology and Laboratory Medicine, British Columbia Children's Hospital, Vancouver, BC, Canada.
Hilary VallanceDepartment of Pathology and Laboratory Medicine, British Columbia Children's Hospital, Vancouver, BC, Canada.
Graham SinclairDepartment of Pathology and Laboratory Medicine, British Columbia Children's Hospital, Vancouver, BC, Canada.
BC Children's Hospital · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inborn errors of propionate, cobalamin and methionine metabolism are targets for Newborn Screening (NBS) in most programs world-wide, and are primarily screened by analyzing for propionyl carnitine (C3) and methionine in dried blood spot (DBS) cards using tandem mass spectrometry (MS/MS). Single-tier NBS approaches using C3 and methionine alone lack specificity, which can lead to an increased false-positive rate if conservative cut-offs are applied to minimize the risk of missing cases. Implementation of liquid chromatography tandem mass spectrometry (LC-MS/MS) second-tier testing for 2-methylcitric acid (MCA), methylmalonic acid (MMA), and homocysteine (HCY) from the same DBS card can improve disease screening performance by reducing the false-positive rate and eliminating the need for repeat specimen collection. However, DBS analysis of MCA, MMA, and HCY by LC-MS/MS is challenging due to limited specimen size and analyte characteristics leading to a combination of low MS/MS sensitivity and poor reverse-phase chromatographic retention. Sufficient MS response and analytical performance can be achieved for MCA by amidation using DAABD-AE and by butylation for MMA and HCY. Herein we describe the validation of a second-tier dual derivatization LC-MS/MS approach to detect elevated MCA, MMA, and HCY in DBS cards for NBS. Clinical utility was demonstrated by retrospective analysis of specimens, an interlaboratory method comparison, and assessment of external proficiency samples. Imprecision was <10.8% CV, with analyte recoveries between 90.2 and 109.4%. Workflows and analytical performance characteristics of this second-tier LC-MS/MS approach are amenable to implementation in the NBS laboratory.

Indexed as

2-Methylcitric acidC2, acetylcarnitineC3, propionylcarnitineCbl, cobalaminCBS, cystathionine β-synthaseDAABD-AE, 4-[2-(N,N-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazoleDBS, dried blood spotDMAP, 4-(dimethylamino)pyridineDTT, dithiothreitolEDC, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlorideESI, electrospray ionizationFA, formic acidGC, gas chromatographyGPCho’s, glycerophosphocholinesHCl, hydrochloric acidHCY, homocysteineHomocysteineLC, liquid chromatographyLLOD, lower limit of detectionLLOQ, lower limit of quantitationMass spectrometryMCA, 2-methylcitric acidMethylmalonic acidMet, methionineMMA, methylmalonic acidMPs, mobile phasesMRM, multiple reaction monitoringMS, mass spectrometryMS/MS, tandem mass spectrometryNBS, newborn screeningNewborn screeningPhe, phenylalaninePPV, positive predictive valueQC, quality controlrpm, revolutions per minuteSecond-tierS/N, signal-to-noise

Identifiers

PMID34820666
PMCPMC8601015
OpenAlexW3139421153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.